Measuring Change Of Hrqol Patients During Japan Treated By Eltrombopag

1425 Words Dec 17th, 2015 6 Pages
Final Paper: Measuring Change in HRQoL of ITP Patients in Japan treated by Eltrombopag
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder, which is characterized by a low platelet count caused by both increased platelet destruction and insufficient platelet production [1]. In Japan, there are 20,000 patients with ITP and the incidence of ITP is estimated at 3,000 per year [2]. Major signs and symptoms include red spots and/or bruising on the skin, prolonged bleeding, nosebleeds, heavy menstrual flow, and fatigue [3]. Patients with IPT are tired, depressed, have muscle aches, mood swings, dread the next platelet count, or are plain scared, imposing extensive restrictions on patients’ physical, mental, social and functional activities [4].
The goal of treating ITP is to ensure a sufficient platelet count and to prevent bleeding complications while minimizing treatment side effects [5]. According to the American Society of Hematology guideline, the first line medication to treat the disease is corticosteroids [6]. However, long-term use of corticosteroids isn 't recommended in the guideline because of the risk of serious side effects. Alternative treatment option for ITP is thrombopoietin (TPO) receptor agonists, which help bone marrow produce more platelets, preventing bruising and bleeding. In the global pivotal study, it has been demonstrated that TPO receptor agonists, Eltrombopag significantly improves platelet counts of patients with ITP in…

Related Documents